<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707809</url>
  </required_header>
  <id_info>
    <org_study_id>201512039MINB</org_study_id>
    <nct_id>NCT02707809</nct_id>
  </id_info>
  <brief_title>Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient</brief_title>
  <official_title>Effects of Perioperative Dexmedetomidine Infusion on Microcirculation and Kidney and Intestinal Injury in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The microcirculation is altered in acute kidney injury and chronic kidney disease. The&#xD;
      microcirculation is poor in end-stage renal disease patients receiving hemodialysis. Kidney&#xD;
      transplant can improve the life quality of these patients. However, surgical stress and&#xD;
      inflammatory response may cause microcirculatory dysfunction and intestinal injury. Moreover,&#xD;
      the transplanted kidney would suffer from the ischemia and reperfusion injury, and it may&#xD;
      result in acute kidney injury. In ischemia and reperfusion injury animal model,&#xD;
      dexmedetomidine has been proven to attenuate kidney and intestinal injury. In our previous&#xD;
      study of surgical stress and pain stimulation rat model, we found that dexmedetomidine&#xD;
      attenuate the intestinal microcirculatory dysfunction. In patients receiving coronary artery&#xD;
      bypass graft surgery, dexmedetomidine increases urine output and decreases postoperative&#xD;
      serum level of neutrophil gelatinase-associated lipocalin.&#xD;
&#xD;
      This study aims to investigate whether perioperative dexmedetomidine infusion may attenuate&#xD;
      microcirculatory dysfunction, kidney injury, and intestinal injury for patients undergoing&#xD;
      kidney transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The microcirculation is altered in acute kidney injury and chronic kidney disease. The&#xD;
      microcirculation is poor in end-stage renal disease patients receiving hemodialysis. Kidney&#xD;
      transplant can improve the life quality of these patients. However, surgical stress and&#xD;
      inflammatory response may cause microcirculatory dysfunction and intestinal injury. Moreover,&#xD;
      the transplanted kidney would suffer from the ischemia and reperfusion injury, and it may&#xD;
      result in acute kidney injury. In ischemia and reperfusion injury animal model,&#xD;
      dexmedetomidine has been proven to attenuate kidney and intestinal injury. In our previous&#xD;
      study of surgical stress and pain stimulation rat model, we found that dexmedetomidine&#xD;
      attenuate the intestinal microcirculatory dysfunction. In patients receiving coronary artery&#xD;
      bypass graft surgery, dexmedetomidine increases urine output and decreases postoperative&#xD;
      serum level of neutrophil gelatinase-associated lipocalin. The aim of this study is to&#xD;
      investigate whether perioperative dexmedetomidine infusion may attenuate microcirculatory&#xD;
      dysfunction, kidney injury, and intestinal injury for patients undergoing kidney transplant.&#xD;
&#xD;
      This is a randomized, single-blind, prospective, controlled clinical trial. The patients will&#xD;
      be randomly assigned to the control group or dexmedetomidine group. After induction of&#xD;
      anesthesia, the patients in the control group will receive regular perioperative care. The&#xD;
      patients in the dexmedetomidine group will receive perioperative dexmedetomidine continuous&#xD;
      intravenous infusion after induction of anesthesia till 2 hours after the end of the&#xD;
      operation. All patients will receive sublingual microcirculation examination, laboratory&#xD;
      tests of blood urine nitrogen, creatinine, and enzyme-linked immunosorbent assays of serum&#xD;
      level of endocan, diamine oxidase, and neutrophil gelatinase-associated lipocalin at preset&#xD;
      time points. The urine level of neutrophil gelatinase-associated lipocalin will also be&#xD;
      measured. The vital signs and urine output will be recorded. The difference between the two&#xD;
      groups will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total small vessel density of sublingual microcirculation</measure>
    <time_frame>Postoperative 2h</time_frame>
    <description>Sublingual microcirculation captured using an incident dark-field video microscope</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>Postoperative day 2</time_frame>
    <description>Difference in serum creatine levels between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine anesthesia care for kidney transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine infusion</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  kidney transplant recipient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic history to dexmedetomidine&#xD;
&#xD;
          -  refractory bradycardia &lt; 60 bpm despite treatment&#xD;
&#xD;
          -  severe atrioventricular block (2nd and 3rd degree)&#xD;
&#xD;
          -  previous operation of tongue&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Chang Yeh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

